WASHINGTON — A nanomicellar formulation of cyclosporine A was well tolerated with a low rate of ocular adverse events or instillation site pain, according to a study presented here.
“The OTX-101 formulation was found in this clinical trial to be superior to vehicle in both increasing tear production and improving corneal and conjunctival staining after 12 weeks of therapy in patients with keratoconjunctivitis sicca,” Jodi Luchs, MD, FACS, said at the American Society of Cataract and Refractive Surgery meeting.
Luchs reported the results of a phase 3 study assessing the ocular
Uncategorized